Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Rocket Pharmaceuticals (RCKT) Net Margin: 2016-2025

Historic Net Margin for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Sep 2025 value amounting to 10,641.01%.

  • Rocket Pharmaceuticals' Net Margin fell 352438.00% to 10,641.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 12,739.93%, marking a year-over-year decrease of 96581.00%. This contributed to the annual value of 13,719.30% for FY2024, which is 62090.00% up from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Net Margin stood at 10,641.01%, which was down 26.97% from 14,570.61% recorded in Q2 2025.
  • Rocket Pharmaceuticals' 5-year Net Margin high stood at 14,786.84% for Q2 2024, and its period low was 2,323.83% during Q1 2021.
  • Its 3-year average for Net Margin is 13,225.69%, with a median of 13,174.95% in 2024.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Net Margin surged by 1,235,296bps in 2021 and then tumbled by 352,438bps in 2025.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Net Margin stood at 9,556.59% in 2021, then spiked by 473,099bps to 14,287.58% in 2022, then crashed by 159,396bps to 12,693.62% in 2023, then soared by 6,051bps to 12,754.12% in 2024, then slumped by 352,438bps to 10,641.01% in 2025.
  • Its Net Margin stands at 10,641.01% for Q3 2025, versus 14,570.61% for Q2 2025 and 12,994.49% for Q1 2025.